The beneficial effects of glycoprotein IIb/IIIa receptor antagonists in preventing ischemic complications during percutaneous coronary intervention have been established in a series of controlled ...
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
The National Institute for Clinical Excellence (NICE, or the Institute) is reviewing its guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes, which was ...
This is a preview. Log in through your library . Abstract On platelets the membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) functions in adhesive interactions with fibrinogen, von Willebrand factor ...
Antiplatelet agents form a cornerstone of therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention, as well as in the secondary prevention of cardiovascular ...
RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...
The low rate of intracranial hemorrhage in these trials suggests that, at least in the patient population included in clinical trials, there is no increased risk in comparison to control arms of ...
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
As a part of this appraisal the Institute has commissioned an Assessment Report, which is a critical review of the clinical and cost effectiveness of the technology prepared by an independent group.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback